Takeda Pharmaceutical to acquire Shire

Takeda Pharmaceutical announced it has entered into an agreement to acquire Shire for approximately 46 billion pounds, or 49.01 pounds per Shire share.

Takeda also announced a “364-day bridge credit agreement” for an aggregate principal amount of up to $30.85 billion to fund the acquisition. Under the terms of the acquisition, every Shire shareholders will be entitled to $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda American depositary shares, according to company press releases.

After closing, Takeda shareholders will own approximately 50% of the combined group.

Shire’s board recently said it would possibly recommend its shareholders accept a bid from the Japanese-based pharmaceutical company. It initially rejected Takeda’s original proposal to acquire Shire for 46.50 pounds per share.

The acquisition is expected to close in the first half of 2019.

Takeda Pharmaceutical announced it has entered into an agreement to acquire Shire for approximately 46 billion pounds, or 49.01 pounds per Shire share.

Takeda also announced a “364-day bridge credit agreement” for an aggregate principal amount of up to $30.85 billion to fund the acquisition. Under the terms of the acquisition, every Shire shareholders will be entitled to $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda American depositary shares, according to company press releases.

After closing, Takeda shareholders will own approximately 50% of the combined group.

Shire’s board recently said it would possibly recommend its shareholders accept a bid from the Japanese-based pharmaceutical company. It initially rejected Takeda’s original proposal to acquire Shire for 46.50 pounds per share.

The acquisition is expected to close in the first half of 2019.